Sarah Watson

Dr. Sarah Watson

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Nature
Verified
Journal Article
Open access
PDF file
SSStéphanie Solier
Stéphanie Solier
SMSebastian Müller
Sebastian Müller
TCTatiana Cañeque
Tatiana Cañeque
AVAntoine Versini
Antoine Versini
AMArnaud Mansart
Arnaud Mansart
RRRaphaël Rodriguez
Raphaël Rodriguez
Inflammation is a complex physiological process triggered in response to harmful stimuli1. It involves cells of the immune system capable of clearing sources of injury and damaged tissues. Excessive inflammation can occur as a result of infection and is a hallmark of several diseases2–4. The molecular bases underlying inflammatory responses are not fully understood. Here we show that the cell surface glycoprotein CD44, which marks the acquisition of distinct cell phenotypes in the context of development, immunity and cancer progression, mediates the uptake of metals including copper. We identify a pool of chemically reactive copper(ii) in mitochondria of inflammatory macrophages that catalyses NAD(H) redox cycling by activating hydrogen peroxide. Maintenance of NAD+ enables metabolic and epigenetic programming towards the inflammatory state. Targeting mitochondrial copper(ii) with supformin (LCC-12), a rationally designed dimer of metformin, induces a reduction of the NAD(H) pool, leading to metabolic and epigenetic states that oppose macrophage activation. LCC-12 interferes with cell plasticity in other settings and reduces inflammation in mouse models of bacterial and viral infections. Our work highlights the central role of copper as a regulator of cell plasticity and unveils a therapeutic strategy based on metabolic reprogramming and the control of epigenetic cell states.

7 May 2025 in Nature
Verified
Journal Article
Open access
PDF file
TCTatiana Cañeque
Tatiana Cañeque
LBLeeroy Baron
Leeroy Baron
SMSebastian Müller
Sebastian Müller
ACAlanis Carmona
Alanis Carmona
LCLudovic Colombeau
Ludovic Colombeau
RRRaphaël Rodriguez
Raphaël Rodriguez
Iron catalyses the oxidation of lipids in biological membranes and promotes a form of cell death called ferroptosis1. Defining where this chemistry occurs in the cell can inform the design of drugs capable of inducing or inhibiting ferroptosis in various disease-relevant settings. Genetic approaches have revealed suppressors of ferroptosis2,3,4; by contrast, small molecules can provide spatiotemporal control of the chemistry at work5. Here we show that the ferroptosis inhibitor liproxstatin-1 exerts cytoprotective effects by inactivating iron in lysosomes. We also show that the ferroptosis inducer RSL3 initiates membrane lipid oxidation in lysosomes. We designed a small-molecule activator of lysosomal iron—fentomycin-1—to induce the oxidative degradation of phospholipids and ultimately ferroptosis. Fentomycin-1 is able to kill iron-rich CD44high primary sarcoma and pancreatic ductal adenocarcinoma cells, which can promote metastasis and fuel drug tolerance. In such cells, iron regulates cell adaptation6,7 while conferring vulnerability to ferroptosis8,9. Sarcoma cells exposed to sublethal doses of fentomycin-1 acquire a ferroptosis-resistant cell state characterized by the downregulation of mesenchymal markers and the activation of a membrane-damage response. This phospholipid degrader can eradicate drug-tolerant persister cancer cells in vitro and reduces intranodal tumour growth in a mouse model of breast cancer metastasis. Together, these results show that control of iron reactivity confers therapeutic benefits, establish lysosomal iron as a druggable target and highlight the value of targeting cell states10.

18 May 2021 in Cells
Verified
Journal Article
Open access
PDF file
TATAREK Assi
TAREK Assi
SWSarah Watson
Sarah Watson
BSBachar Samra
Bachar Samra
ERElie Rassy
Elie Rassy
ACAxel Le Cesne
Axel Le Cesne
OMOlivier Mir
Olivier Mir
Osteosarcoma is the most common primary tumor of the bones affecting mainly young adults. Despite the advances in the field of systemic anticancer therapy, the prognosis of relapsed of metastatic osteosarcoma patients remain dismal with very short survival. However, the better understanding of the pathophysiology of this subtype of sarcoma has led to the identification of new targeted agents with significant activity. In fact, increased angiogenesis plays a major role in the tumor growth and survival of osteosarcoma patients. Several targeted agents have demonstrated a significant anti-tumor activity including multi-kinase inhibitors. In this review, we will discuss the pathophysiology, rationale, and role of targeting angiogenesis via the VEGF pathway in patients with osteosarcoma with emphasis on the published clinical trials and future directions.

1 October 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
JVJulien Vibert
Julien Vibert
PGPierron Gaelle
Pierron Gaelle
CBCamille Benoist
Camille Benoist
NGNadège Gruel
Nadège Gruel
DGDelphine Guillemot
Delphine Guillemot
SWSarah Watson
Sarah Watson

12 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NGNadège Gruel
Nadège Gruel
CQChloé Quignot
Chloé Quignot
LLLAETITIA LESAGE
LAETITIA LESAGE
SZSophie El Zein
Sophie El Zein
SBSylvie Bonvalot
Sylvie Bonvalot
SWSarah Watson
Sarah Watson
Dedifferentiated liposarcoma (DDLPS) is the most frequent high-grade soft tissue sarcoma subtype. It is characterized by a component of undifferentiated tumor cells coexisting with a component of well-differentiated adipocytic tumor cells. Both dedifferentiated (DD) and well-differentiated (WD) components exhibit MDM2 amplification, however their cellular origin remains elusive. Using single-cell RNA sequencing, DNA sequencing, in situ multiplex immunofluorescence and functional assays in paired WD and DD components from primary DDLPS tumors, we characterize the cellular heterogeneity of DDLPS tumor and micro-environment. We identify a population of tumor adipocyte stem cells (ASC) showing striking similarities with adipocyte stromal progenitors found in white adipose tissue. We show that tumor ASC harbor the ancestral genomic alterations of WD and DD components, suggesting that both derive from these progenitors following clonal evolution. Last, we show that DD tumor cells keep important biological properties of ASC including pluripotency and that their adipogenic properties are inhibited by a TGF-β-high immunosuppressive tumor micro-environment.

30 September 2023 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SBSylvie Bonvalot
Sylvie Bonvalot
NCNathalie Cozic
Nathalie Cozic
ACAxel Le Cesne
Axel Le Cesne
Jaen-Yves BlayJaen-Yves Blay
Jaen-Yves Blay
NPNicolas Penel
Nicolas Penel
LLLaurent Lam
Laurent Lam